Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., le Beau, M. M. et al. The 2016 revision to the World Well being Group classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405 (2016).
Kroeze, E., Loeffen, J. L. C., Poort, V. M. & Meijerink, J. P. P. T-cell lymphoblastic lymphoma and leukemia: completely different illnesses from a standard premalignant progenitor? Blood Adv 4, 3466–3473 (2020).
van der Zwet, J. C. G., Cordo’, V., Canté-Barrett, Ok. & Meijerink, J. P. P. Multi-omic approaches to enhance consequence for T-cell acute lymphoblastic leukemia sufferers. Adv Biol Regul 74, 100647 (2019).
Burkhardt, B., Zimmermann, M., Oschlies, I., Niggli, F., Mann, G., Parwaresch, R. et al. The impression of age and gender on biology, medical options and remedy consequence of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 131, 39–49 (2005).
Burkhardt, B., Reiter, A., Landmann, E., Lang, P., Lassay, L., Dickerhoff, R. et al. Poor consequence for youngsters and adolescents with progressive illness or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group. J Clin Oncol 27, 3363–3369 (2009).
Hagedorn, N., Acquaviva, C., Fronkova, E., Von Stackelberg, A., Barth, A., Zur Stadt, U. et al. Submicroscopic bone marrow involvement in remoted extramedullary relapses in childhood acute lymphoblastic leukemia: a extra exact definition of “remoted” and its potential medical implications, a collaborative examine of the Resistant Illness Committee of the Worldwide BFM examine group. Blood 110, 4022–4029 (2007).
Basso, Ok., Mussolin, L., Lettieri, A., Brahmachary, M., Lim, W. Ok., Califano, A. et al. T-cell lymphoblastic lymphoma exhibits variations and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Most cancers 50, 1063–1075 (2011).
Bonn, B. R., Big, A., Rohde, M., Oschlies, I., Klapper, W., Voss, R. et al. Complete exome sequencing hints at a novel mutational profile of paediatric T-cell lymphoblastic lymphoma. Br J Haematol vol. 168 308–313 (2015).
Feng, H., Stachura, D. L., White, R. M., Gutierrez, A., Zhang, L., Sanda, T. et al. T-lymphoblastic lymphoma cells categorical excessive ranges of BCL2, S1P1, and ICAM1, resulting in a blockade of tumor cell intravasation. Most cancers Cell 18, 353–366 (2010).
Patel, J. L., Smith, L. M., Anderson, J., Abromowitch, M., Campana, D., Jacobsen, J. et al. The immunophenotype of T-lymphoblastic lymphoma in kids and adolescents: A kids’s oncology group report. Br J Haematol 159, 454–461 (2012).
Bernard, A., Boumsell, L., Reinherz, E., Nadler, L., Ritz, J., Coppin, H. et al. Cell floor characterization of malignant T cells from lymphoblastic lymphoma utilizing monoclonal antibodies: proof for phenotypic variations between malignant T cells from sufferers with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood 57, 1105–1110 (1981).
Uyttebroeck, A., Vanhentenrijk, V., Hagemeijer, A., Boeckx, N., Renard, M., Wlodarska, I. et al. Is there a distinction in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma? Leuk Lymphoma 48, 1745–1754 (2007).
Haider, Z., Landfors, M., Golovleva, I., Erlanson, M., Schmiegelow, Ok., Flægstad, T. et al. DNA methylation and replica quantity variation profiling of T-cell lymphoblastic leukemia and lymphoma. Blood Most cancers J 10, 45 (2020).
Terwilliger, T. & Abdul-Hay, M. Acute lymphoblastic leukemia: a complete evaluation and 2017 replace. Blood Most cancers J. 7, e577 (2017).
Pillon, M., Piglione, M., Garaventa, A., Conter, V., Giuliano, M., Arcamone, G. et al. Lengthy-term outcomes of AIEOP LNH-92 protocol for the remedy of pediatric lymphoblastic lymphoma: a report of the Italian affiliation of pediatric hematology and oncology. Pediatr Blood Most cancers 53, 953–959 (2009).
Goldberg, J. M., Silverman, L. B., Levy, D. E., Dalton, V. Ok., Gelber, R. D., Lehmann, L. et al. Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Most cancers Institute Acute Lymphoblastic Leukemia Consortium expertise. J Clin Oncol vol. 21 3616–3622 (2003).
Sandlund, J. T., Pui, C. H., Zhou, Y., Behm, F. G., Onciu, M., Razzouk, B. I. et al. Efficient remedy of advanced-stage childhood lymphoblastic lymphoma with out prophylactic cranial irradiation: Outcomes of St Jude NHL13 examine. Leukemia 23, 1127–1130 (2009).
Huguet, F., Chevret, S., Leguay, T., Thomas, X., Boissel, N., Escoffre-Barbe, M. et al. Intensified remedy of acute lymphoblastic leukemia in adults: Report of the randomized GRAALL-2005 medical trial. J Clin Oncol 36, 2514–2523 (2018).
Oudot, C., Auclerc, M. F., Levy, V., Porcher, R., Piguet, C., Perel, Y. et al. Prognostic components for leukemic induction failure in kids with acute lymphoblastic leukemia and consequence after salvage remedy: The FRALLE 93 examine. J Clin Oncol 26, 1496–1503 (2008).
Burkhardt, B., Taj, M., Garnier, N., Minard-Colin, V., Hazar, V., Mellgren, Ok. et al. Therapy and consequence evaluation of 639 relapsed non-hodgkin lymphomas in kids and adolescents and ensuing remedy suggestions. Cancers 13, 2075 (2021).
Trinquand, A., Tanguy-Schmidt, A., Abdelali, R. Ben, Lambert, J., Beldjord, Ok., Lengliné, E. et al. Towards a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic danger classification of grownup T-Cell acute lymphoblastic leukemia: a gaggle for analysis in grownup acute lymphoblastic leukemia examine. J Clin Oncol 31, 4333–4342 (2013).
Bond, J., Marchand, T., Touzart, A., Cieslak, A., Trinquand, A., Sutton, L. et al. An early thymic precursor phenotype predicts consequence solely in HOXA-overexpressing grownup T-cell acute lymphoblastic leukemia: A bunch for analysis in grownup acute lymphoblastic leukemia examine. Haematologica 101, 732–740 (2016).
Alcazer, V. StatAid: An R package deal with a graphical person interface for knowledge evaluation. J. Open Supply Softw 5, 2630 (2020).
Dadi, S., Le Noir, S., Payet-Bornet, D., Lhermitte, L., Zacarias-Cabeza, J., Bergeron, J. et al. TLX Homeodomain Oncogenes Mediate T Cell Maturation Arrest in T-ALL by way of Interplay with ETS1 and Suppression of TCRα Gene Expression. Most cancers Cell 21, 563–576 (2012).
Cavé, H., Suciu, S., Preudhomme, C., Poppe, B., Robert, A., Uyttebroeck, A. et al. Medical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: Outcomes of EORTC research 58881 and 58951. Blood 103, 442–450 (2004).
Ballerini, P., Landman-Parker, J., Cayuela, J. M., Asnafi, V., Labopin, M., Gandemer, V. et al. Impression of genotype on survival of kids with T-cell acute lymphoblastic leukemia handled in line with the French protocol FRALLE-93: the impact of TLX3/HOX11L2 gene expression on consequence. Haematologica 93, 1658–1665 (2008).
Balbach, S. T., Makarova, O., Bonn, B. R., Zimmermann, M., Oschlies, I., Klapper, W. et al. Proposal of a genetic classifier for danger group stratification in pediatric T-cell lymphoblastic lymphoma reveals variations from grownup T-cell lymphoblastic leukemia. Leukemia vol. 30 970–973 (2016).
Khanam, T., Sandmann, S., Seggewiss, J., Ruether, C., Zimmermann, M., Norvil, A. B. et al. I Integrative genomic evaluation of pediatric T-cell lymphoblastic lymphoma reveals candidates of medical significance. Blood 137, 2347–2359 (2021).
Gutierrez, A., Sanda, T., Grebliunaite, R., Carracedo, A., Salmena, L., Ahn, Y. et al. Excessive frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647–650 (2009).
Zuurbier, L., Petricoin, E. F., Vuerhard, M. J., Calvert, V., Kooi, C., Buijs- Gladdines, J. G. C. A. M. et al. The importance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica 97, 1405–1413 (2012).
Li, Z., Track, Y., Zhang, Y., Li, C., Wang, Y., Xue, W. et al. Genomic and consequence evaluation of grownup T-cell lymphoblastic lymphoma. Haematologica vol. 105 E107–E110 (2020).
Fayard, E., Moncayo, G., Hemmings, B. A. & Holländer, G. A. Phosphatidylinositol 3-kinase signaling in thymocytes: The necessity for stringent management. Sci Sign. 3, 1–13 (2010).
Chen, Y., Hou, Q., Yan, W., J, L., D, C., Z, L. et al. PIK3CA is vital for the proliferation, invasiveness, and drug resistance of human tongue carcinoma cells. Oncol Res. 19, 563–571 (2011).
Matsuoka, T., Yashiro, M., Nishioka, N., Hirakawa, Ok., Olden, Ok. & Roberts, J. D. PI3K/Akt signalling is required for the attachment and spreading, and progress in vivo of metastatic scirrhous gastric carcinoma. Br J Most cancers 106, 1535–1542 (2012).
Li, B., Xu, W., Lam, A., Y, W., HF, H., XY, G. et al. S Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a goal for anti-metastasis remedy. Oncotarget 8, 38755–38766 (2017).
Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A. & Martini, M. PI3K in most cancers–stroma interactions: unhealthy in seed and ugly in soil. Oncogene 2014 33:24 33, 3083–3090 (2013).
Venot, Q., Blanc, T., Rabia, S. H., Berteloot, L., Ladraa, S. & Duong, J. et al. Focused remedy in sufferers with PIK3CA-related overgrowth syndrome. Nature 558, 540–546 (2021).
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Constructive Superior Breast Most cancers. N Engl J Med. 380, 1929–1940 (2019).
Weng, A. P., Ferrando, A. A., Lee, W., Morris IV, J. P., Silverman, L. B., Sanchez- Irizarry, C. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269–271 (2004).
Aref, S., el Agdar, M., Salama, O., Zeid, T. A. & Sabry, M. Significance of NOTCH1 mutations detections in T-acute lymphoblastic leukemia sufferers. Most cancers Biomark 27, 157–162 (2020).
Clappier, E., Collette, S., Grardel, N., Girard, S., Suarez, L., Brunie, G. et al. NOTCH1 and FBXW7 mutations have a good impression on early response to remedy, however not on consequence, in kids with T-cell acute lymphoblastic leukemia (T-ALL) handled on EORTC trials 58881 and 58951. Leukemia 24, 2023–2031 (2010).
Breit, S., Stanulla, M., Flohr, T., Schrappe, M., Ludwig, W. D., Tolle, G. et al. Activating NOTCH1 mutations predict favorable early remedy response and long-term consequence in childhood precursor T-cell lymphoblastic leukemia. Blood 108, 1151–1157 (2006).
Bonn, B. R., Rohde, M., Zimmermann, M., Krieger, D., Oschlies, I., Niggli, F. et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood 121, 3153–3160 (2013).
Lepretre, S., Touzart, A., Vermeulin, T., Picquenot, J. M., Tanguy-Schmidt, A., Salles, G. et al. Pediatric-like acute lymphoblastic leukemia remedy in adults with lymphoblastic lymphoma: the GRAALL-LYSA LL03 examine. J Clin Oncol. 34, 572–580 (2016).
Schäfer, V., Ernst, J., Rinke, J., Winkelmann, N., Beck, J. F., Hochhaus, A. et al. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia. J Most cancers Res Clin Oncol 142, 1641–1650 (2016).
Ntziachristos, P., Tsirigos, A., Vlierberghe, P. Van, Nedjic, J., Trimarchi, T.,Flaherty, M. S. et al. Genetic inactivation of the polycomb repressive advanced 2 in T cell acute lymphoblastic leukemia. Nat Med 18, 296–301 (2012).
Andrieu, G. P., Kohn, M., Simonin, M., Smith, C., Cieslak, A., Dourthe, M.-E. et al. PRC2 lack of operate confers a targetable vulnerability to BET proteins in T-ALL. Blood 138, 1855–1869 (2021).
Broux, M., Prieto, C., Demeyer, S., Bempt, M. vanden, Alberti-Servera, L., Lodewijckx, I. et al. Suz12 inactivation cooperates with JAK3 mutant signaling within the growth of T-cell acute lymphoblastic leukemia. Blood 134, 1323-1336 (2019).
Yuan, S., Wang, X., Hou, S., Guo, T., Lan, Y., Yang, S. et al. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia development. Leukemia 36, 370–382 (2022).
Kurzer, J. H. & Weinberg, O. Ok. PHF6 mutations in hematologic malignancies. Entrance Oncol 11, 704471 (2021).
Liu, Y., Easton, J., Shao, Y., Maciaszek, J., Wang, Z., Wilkinson, M. R. et al. The genomic panorama of pediatric and younger grownup T-lineage acute lymphoblastic leukemia. Nat Genet 49, 1211–1218 (2017).
Zhang, H., Wang, H., Qian, X., Gao, S., Xia, J., Liu, J. et al Genetic mutational evaluation of pediatric acute lymphoblastic leukemia from a single heart in China utilizing exon sequencing. BMC Most cancers 20, 211 (2020).
Stengel, A., Kern, W., Haferlach, T., Schnittger, S., Zenger, M. & Haferlach, C. Comparability of TP53 Alterations in Hematological Malignancies. Blood 126, 4819–4819 (2015).
Cluzeau, T., Sebert, M., Rahmé, R., Cuzzubbo, S., Lehmann-Che, J., Madelaine, I. et al. Eprenetapopt Plus Azacitidine In TP53-mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Part Ii Examine by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol 39, 1575–1583 (2021).
Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A. et al. Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes. J Clin Oncol 39, 1584–1594 (2021).
Li, Y., Buijs-Gladdines, J. G. C. A. M., Canté-Barrett, Ok., Stubbs, A. P., Vroegindeweij, E. M., Smits, W. Ok. et al. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T Cell Acute Lymphoblastic Leukemia: A Genome Sequencing Examine. PLoS Med 13, e1002200 (2016).
Delgado-Martin, C., Meyer, L. Ok., Huang, B. J., Shimano, Ok. A., Zinter, M. S., Nguyen, J. v et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia 2017 31:12 31, 2568–2576 (2017).
Senkevitch, E., Hixon, J., Andrews, C., Barata, J. T., Li, W. & Durum, S. The JAK inhibitor ruxolitinib is efficient in treating T cell acute lymphoblastic leukemia with acquire of operate mutations in IL-7R alpha. Blood 126, 1330–1330 (2015).
Cabannes, A., Schmidt, A., Brissot, E., Balsat, M., Maury, S., Isnard, F. et al. The mix of Venetoclax and Tofacitinib Induced Hematological Responses in Sufferers with Relapse/ Refractory T-ALL with BCL2 Expression and Floor IL7R Expression or IL7R-Pathway Mutations (On Behalf of the GRAALL). Blood 134, 1339 (2019).